change in HMTT in the pravastatin group was -0.18 seconds (-5%) and in the placebo group +0.52 seconds (+18%), a difference of 0.70 seconds (P^.004). The mean difference in change in classification of angina pectoris (scale, 1 to 4) between pravastatin and placebo was 0.7 (P=.03) in favor of the pravastatin-treated patients. The change in HMTT was correlated with the change in exercise time (r= -.65, P=.002).
Methods and Results
In a substudy of REGRESS, 69 pa tients were randomized to pravastatin or placebo. Thirty-seven of these patients were allocated to the medical management stratum. Quantitative coronary angiography, regional myocar dial perfusion, exercise testing, and classification of angina pectoris were assessed at baseline and after 2 years of therapy.
Regional myocardial perfusion was assessed by digital subtrac tion angiography after intracoronary papaverine with videodensitometric calculation of the hyperemic mean transit time (HMTT) of contrast. In the medical management stratum, regional myocardial perfusion was assessed in 31 regions in the pravastatin group and 25 regions in the placebo group. The I n the multifactorial pathogenesis of coronary ath erosclerosis, an elevated cholesterol level is a causal factor.1 Numerous studies have shown that in patients with coronary artery disease, HMG-coenzyme A reductase inhibitors have a beneficial effect on the incidence of cardiovascular events and development of coronary atherosclerosis.2" 7 In several angiographic trials, the reduction of clinical events was more pro nounced than would be expected by the modest influ ence of lipid lowering on progression of atherosclerosis, which suggests the possibility of a plaque stabilizing effect.7» 8 In normal coronary arteries, the endothelium produces endothelium-derived relaxing factor, which protects the vessel wall by inhibiting platelet adhesion and aggregation, smooth muscle cell proliferation, and smooth muscle cell contraction. Atherosclerosis and hypercholesterolemia have a detrimental effect on endo-thelial function in both the epicardial coronary arteries and the resistance vessels.9-11 Exercise induces a meta bolic vasodilatation in the resistance vessels and a flowmediated dilatation of the epicardial vessels, which is endothelium dependent.12 Endothelial dysfunction leads to paradoxical vasoconstriction with impairment of myo cardial perfusion and contributes to the pathogenesis of myocardial ischemia. Cholesterol lowering may restore the endothelial function.13'15 Translated to the clinical situation, lipid-lowering therapy should have a beneficial effect on maximal myocardial perfusion and the occur rence of myocardial ischemia. The impact of lipidlowering drugs on functional parameters such as myo cardial perfusion, exerciserinduced ischem ia, and anginal complaints in patients with coronary atheroscle rosis is not well known. In this study, we evaluated the functional effect of pravastatin therapy and compared the results with the anatomic evaluation by QCA in symptomatic patients with normal to moderately ele vated cholesterol.
Methods
REGRESS is a double-blind, placebo-controlled, multi center study designed to assess the effect of 2 years of treat ment with the HMG-coenzyme A reductase inhibitor pravasta tin on progression and regression of angiographically documented coronary atherosclerosis in male patients with a cholesterol level between 4 and 8 mmol/L (155 and 310 mg/dL).
Patients participating in this study were recruited from the waiting list of patients scheduled to undergo coronary angiog-Circulation Voi 96, N o 2 July 15, 1997 Selected Abbreviations and Acronyms CABG ~ coronary artery bypass graft surgery HM TT = hyperemic mean transit time M OD = minimal obstruction diameter MSD = mean segment diameter PTCA = percutaneous transluminal coronary angioplasty QCA = quantitative coronary angiography REGRESS -Regression Growth Evaluation Statin Study raphy. Patients who were included at the University Hospital Nijmegen underwent, in addition to the REGRESS protocol, assessment of regional myocardial perfusion for functional evaluation of the effect of pravastatin. The study was approved by the ethics committee of the University Hospital Nijmegen, and written informed consent was obtained from all patients. In short, included were 18-to 70-year-old male patients with proven coronary artery disease (at least one coronary diameter stenosis s50%). The study design, definition of clinical events, and methods assessment of lipid levels and QCA have been reported previously.7 After cardiac catheterization, patients were stratified in three strata-medical management, PTCA, or CABG-and subsequently randomized to pravastatin 40 mg once daily or placebo. Because bypass grafts and PTCA may have a major impact on flow, distribution of flow, and exercise results, patients who underwent these procedures were ex cluded from functional evaluation of the effect of pravastatin, QCA was evaluated by assessment of MOD and MSD on the basis of per-patient and per-segment measurements.
Assessment of Myocardial Perfusion
Myocardial perfusion was assessed by digital subtraction angiography with videodensitometric calculation of the HMTT of contrast passage through the capillary bed. This method has been developed in our laboratory in accordance with the principles of the indicator dilution theory and has been vali dated in model studies, animal experiments, and humans.16'18 The short-term reproducibility of the method has been evalu ated with a relative difference of 5±5% for repeated measure ments with a correlation coefficient of .97.18 To exclude autoregulatory changes in the coronary circulation and to ensure a constant and maximal vascular volume, the assessment of myocardial perfusion was performed during maximal hyper emia induced by papaverine. The derived time parameter, HMTT, is inversely related to myocardial perfusion. We used this method to compare the maximal regional myocardial perfusion in the areas of the left anterior descending artery, right circumflex artery, and right coronary artery at baseline and at follow-up. The methods of image acquisition, analysis of the time-density curves, and correction of the HMTT to a mean aortic blood pressure of 100 mm Hg and the final calculations of the regional HMTTs have been described previously. 19 Calculation of the HMTTs was performed with blinding to treatment allocation. Effect analysis of the lipid-lowering treat ment was based primarily on the regional change in myocardial perfusion. The patient-based evaluation was performed by averaging the regional HMTT values to one value per patient as a global estimate of myocardial perfusion.
Exercise Testing
Exercise testing was performed at baseline and at follow up after 2 years. Antianginal medication was not discontinued. An electronically braked bicycle ergometer (Marquette Case 15, Marquette Electronics Inc) was used, along with continuous ECG monitoring. The exercise was started at a load of 50 W, followed by a 10-W increase every minute until maximal exercise was achieved, chest discomfort occurred, or usual criteria for stopping a test were applied. Blood pressure was recorded every 2 minutes, directly after maximal exercise, and at rest in the second and fifth minute. Automated calculation was performed of ST-segment depression 80 ms beyond the J-point Variables used for analysis included maximal work load, time until the onset of 0.1-mV (1-mm) horizontal or downsloping ST-segment depression, maximal ST-segment de pression, and maximal rate-pressure product. The patients who underwent nonscheduled interventions in the medical manage ment stratum were excluded from the effect analysis. Patients with an abnormal ECG at the baseline exercise test were also excluded from analysis.
Classification of Angina Pectoris
After randomization at the first visit and at follow-up after 2 years, angina pectoris was classified in all patients according to the Canadian Cardiovascular Society. 20 The data were analyzed in two ways: first, for the whole group, regardless of nonsched uled interventions; second, in the medical management stra tum. However, the moment of classification of the angina pectoris was taken before any nonscheduled intervention.
Statistical Analysis
Comparison of prespecified continuous variables was per formed within the groups by two-sided paired t tests; betweengroup analysis was performed by unpaired t tests and one-way ANOVA. For categorical comparisons, a x 2 test or the Kruskal-Wallis test was performed when appropriate. Correla tions were tested with Pearson's correlation coefficient. Regres sion analysis was used to compare the change in HMTT with change in exercise parameters and change in QCA data. Calculations were performed on a personal computer with the statistical package SPSS for Windows (releases 6.1 and 7.0). A two-sided value of P<.05 was considered significant. Results were expressed as mean±SD unless otherwise indicated.
Results
Sixty-nine patients were included; subsequently, 35 patients were randomized to the pravastatin group and 34 patients to the placebo group. The groups were well matched for demographic variables ( Table 1 ). The final distribution of the study group in the three treatment strata resulted in 37 patients in the medical management stratum (pravastatin, n=19; placebo, n=18), 16 patients in the PTCA stratum, and 16 patients in the CABG stratum. Fifty-seven patients completed the study ac cording to the protocol: 32 patients in the medical management stratum, 11 in the PTCA stratum, and 14 in the CABG stratum. Dropouts were due to refusal of the second cardiac catheterization in 7 patients, death in 3 patients (two sudden deaths-one in the medical man agement stratum and one in the PTCA stratum-and one death in the CABG stratum in a patient who died shortly after CABG because of heart failure), and noncardiac causes in 2 patients. In the medical manage ment stratum, 6 nonscheduled interventions were car ried out: 1 PTCA in the pravastatin group and 4 PTCAs and 1 CABG in the placebo group. Table 2 gives the mean lipid levels at baseline and during the study. Table  3 shows the QCA data of the medical management stratum. During the study, there was no important change in antianginal medication.
Myocardial Perfusion
In the medical management stratum group, compar ative baseline and follow-up digital subtraction angiog raphies were available in 25 patients. Table 4 gives the results of the region-based HMTT assessment in the perfusion areas of the left anterior descending coronary artery, right circumflex artery, and right coronary artery. The baseline value of regional HMTT in the pravastatin group was 3.36±1.03 versus 2.92±0.75 seconds in the placebo group (P=.08). In the per-patient evaluation, the HMTT in the pravastatin group (n=15) changed from 3.33±0.81 to 3.23±0.60 seconds, a difference of -0.10 seconds ( -3%; 75). In the placebo group (n=10), the per-patient HMTT changed from 2.91±0.33 to 3.39±0.59 seconds, a difference of +0.48 seconds (+16%; P=.01). The difference in change between the pravastatin and placebo groups was 0.58 seconds (P=.045). The baseline values of the pravastatin and placebo groups on a per-patient base were not signifi cantly different (P=.14).
In the PTCA stratum group, 11 patients had follow-up cardiac catheterization. PTCA was performed in 12 vessels in these 11 patients. In 1 vessel, repeated PTCA was performed. Baseline and follow-up reg io n a l HMTT values were available in 9 regions of the P T C A vessels and 15 regions of the nonintervention v e sse ls. Table 5 shows the results of regional HMTT in th e PTCA stratum.
Exercise Testing
In the medical management stratum, 24 o f 35 patients had a follow-up exercise test without intercurrent PTCA or CABG. If patients had a nonscheduled PTCA or CABG in the medical management stratum, most often this occurred after a period of progressive o r unstable angina pectoris, and in this setting, no exercise tests were performed. Table 6 gives the effect analysis of the exercise testing in the medical m anagem ent stratum. 
Baseline exercise tests

Classification of Angina Pectoris
In the medical management stratum, th e angina pec toris classifications (at a scale of 1 to 4) fo r the prava statin and placebo groups at baseline were 2/1 ±0.5 and 1.8±0.8; at follow-up, they were 1.4±1.0 a n d 1.7±1.0, respectively. In 3 patients in the placebo grou p and 1 patient in the pravastatin group, follow -u p was not available. The mean difference in change o f angina pectoris classification between pravastatin an d placebo was 0.7 (?=.03; Fig 1) . Values are m ean±SD when appropriate. LAD indicates left anterior descending artery; RCx, right circumflex artery; RCA, right coronary artery.
----------------------------------------------------------------------------------------------------------------Treatment
Difference in mean change between pravastatin and placebo groups (t test).
In the combined PTCA and CABG stratum (n=32), the baseline classification of angina pectoris was 3.1 ±0.6, whereas in the medical management stratum (n^^), the baseline classification was 1.9±0.7 (a differ ence of 1,2, P c.001). At follow-up, the classification of angina pectoris was 1.6±0.8 for the medical manage ment stratum and 1.3±0.5 for the combination of PTCA and CABG strata (a difference of 0.3, P=.12). In the CABG and PTCA strata, angina pectoris reduced from baseline to follow-up in the pravastatin group with 1,7±0.8 and in the placebo group with 1.9±0.9 (P=.52). 
Clinical Events
Discussion
The results of this study show that in patients with coronary artery disease and a cholesterol level between 4 and 8 mmol/L, pravastatin had a favorable effect on regional myocardial perfusion compared with placebo. In the pravastatin group, there was a slight increase in regional myocardial perfusion in the absence of artério graphie evidence of regression, The results of the exer cise tests and classification of angina pectoris, however, were concordant with the assessment of regional myo cardial perfusion. The discrepancy between the im proved myocardial perfusion and the progression of coronary artery disease in the pravastatin group might be explained by an improved endothelium-dependent relaxation.
Myocardial Perfusion
The baseline HMTT values in the placebo group were shorter than those in the pravastatin group, although the difference was not statistically significant. This phenom enon may be explained by the small sample size and more right coronary artery regions in the pravastatin than in the placebo group (13 versus 7, respectively). In general, HMTT values in the right coronary artery region are about 1 second longer, which is the mean time required for contrast passage from the ostium of the right coronary artery to the crux. Because interventions such as CABG and PTCA may also influence myocardial perfusion in remote noninterventional regions, these strata were excluded from effect analysis of pravastatin on myocardial perfusion. Nonintervention regions are the regional HMTTs of the PTCA stratum. Data of pravastatin and placebo groups are pooled for both the intervention and nonintervention regions. The difference in change between intervention and nonintervention regions was significant (P < .05). in MOD may be restricted to one segment. The regional HMTT data were averaged to a mean value per patient on the basis of a mean of 1.6 perfusion areas per patient. The areas of regional HMTT do not necessarily corre spond with the vessel segments that were averaged for the per-patient QCA results. Finally, the expected rela tion of change in myocardial perfusion and coronary diameter is not linear.
21» 22 The results of the determi nation of myocardial perfusion were better related with exercise parameters than with anatomic parameters. The assessment of the relation of the change in QCA param eters and the change in HMTT is hampered by a few problems. The QCA analysis of progression and regres sion was a patient-based comparison, whereas changes
Aengevaeren et al Functional Evaluation of Lipid L o w e r in g
Maximal myocardial perfusion is determined by the resistance in both the conductance vessels and the micro circulation. Because of the method of assessment of the HMTT (sublingual isosorbide dinitrate before the coronary angiography and intracoronary papaverine during the image acquisition), the hyperemia is induced by an endothelium-independent vasodilatation of the resistance vessels and a flow-mediated vasodilatation of the epicardial vessels. The flow-mediated response is endothelium dependent.23 The difference in myocardial perfusion between the pravastatin and placebo groups might be induced by an impaired flow-mediated vasodi latation in the epicardial vessels in response to the induced hyperemia in the resistance vessels in the pla cebo group. This hypothesis is adapted from Gould et al,24 who described this phenomenon in relation to dipyridamole infusion intravenously during PET for flow assessment in lipid-lowering therapy by diet. The admin istration of isosorbite dinitrate just before the coronary angiogram might have blunted the endothelium -depen dent response. However, the difference in change between the pravastatin and placebo groups o f regional myocardial reperfusion are remarkable.
Exercise Testing
Fixed atherosclerotic obstructions and endotheliumdependent relaxation of the resistance a n d epicardial vessels are determinants of exercise capacity and exer cise-induced ischemia. Although the num ber of patients studied was relatively small, the group o f patients on pravastatin showed a trend toward less isch em ia, a lower heart rate at rest, and a better preserved exercise tolerance compared with the placebo group. These effects may be due in part to a preserved or improved endothelial function.
Classification of Angina Pectoris
As could be expected, baseline angina pectoris was worse in the intervention strata (PTCA and CABG) compared with the medical management stratum . Inter ventions have a major impact on the classification of angina pectoris. No additional benefit o f pravastatin could be established in the intervention strata. After 2 years of therapy, the results of the intervention strata were actually better than the medical m anagem ent stra tum. Nonscheduled interventions may cause a confound 434 Circulation Vol 96, No 2 July 15, 1997 ing effect on the analysis of the classification of angina pectoris in the medical management group. For that reason, the classification of angina pectoris before the nonscheduled intervention was considered an end point. The periods of unstable angina were not included be cause they may represent acute plaque rupture and thrombosis rather than progression of fixed coronary artery atherosclerosis. Nevertheless, the clinical benefit of pravastatin treatment in the medical management stratum is evident.
Comparison With Other Studies
The number of studies evaluating lipid-lowering ther apy with assessment of myocardial perfusion is limit ed.24" 28 Thallium-20'1 scintigraphy and PET were used for semiquantitative evaluation. In these studies, myo cardial perfusion defects improved in the actively treated patient groups, without significant changes in coronary anatomy, as measured or supposed. In the "long-term intense risk factor modification study,5' the change in dipyridamole PET images of normalized counts worsened in control subjects by 13.5% and im proved in the experimental group by 4.2%, numbers that correspond very well with our results.27 In some studies, patients in the active treatment group were subjected to a regular exercise program. The effect of training pre cludes a direct comparison of the effect of lipid-lowering therapy on the exercise parameters.25'26 In the short term lipid-lowering study with fluvastatin, the improve ment of perfusion defects is established after only 12 weeks of therapy. The improvement was especially no ticeable in areas of ischemia.28 The positive effects of these studies on myocardial perfusion are not eluci dated. Suggested mechanisms are improved endotheiium-dependent vasodilation, improved collateral circula tion, and changes in blood viscosity. The data of the effect of HMG-coenzyme A reductase inhibitors on blood viscosity are conflicting.29-31 In studies with lovastatin and simvastatin, no effect on blood viscosity was observed, so it is unlikely that a change in blood viscosity caused the changes in myocardial perfusion. Coronary resistance vessels are spared from the development of overt atherosclerosis, but the endothelial function of the microcirculation can be disturbed in the presence of hypercholesterolemia,9 Thus, improved endothelial function remains the most likely explanation for the improvement in myocardial perfusion, which also may affect collateral circulation.
Study Limitations
Evaluation of exercise testing in the PTCA and CABG strata was influenced largely by the intervention, so we decided not to include these data in the effect analysis of pravastatin. Follow-up parameters were not available in several patients in the medical management stratum, mostly because of cardiovascular complications. These dropouts occurred predominantly in the placebo group and may have influenced the results of this study. However, these dropouts most likely caused underesti mation rather than overestimation of the difference in response between the pravastatin and placebo group.
Conclusions
In symptomatic men with coronary artery disease and normal to moderately raised cholesterol levels, pravasta tin therapy for 2 years resulted in a preserved regional myocardial perfusion, whereas this parameter deterio rated in patients on placebo. The group of patients on pravastatin had fewer clinical events and a trend toward preserved exercise capacity. The change in myocardial perfusion was better related with a change in exercise parameters than with a change in anatomic parameters. In lipid-lowering therapy, assessment of myocardial per fusion is advantageous because it represents a combined measure of the resistance to flow by the epicardial vessels and microcirculation. Functional evaluation of the coronary circulation deserves further investigation as a tool for evaluation of lipid-lowering therapy in patients with coronary artery disease because it might better reflect the clinical benefit for the patient.
